Abstract
To the Editor: No published data exist on how to best manage patients who have major bleeding at the time of being treated with dabigatran. Several management algorithms have been proposed,1–3 but suggestions for use of prothrombin complex concentrates (PCC), recombinant factor VIIa, or fresh-frozen plasma are based on ex vivo reversal of abnormal coagulation tests, animal data, and a study of human volunteers1,4 In view of the vacuum of clinical data the study by Zhou et al5 and its conclusion that “the study provides strong evidence that PCC prevent excess …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
